Ensign Peak Advisors
NVAX icon

Ensign Peak Advisors’s Novavax NVAX Stock Holding History

Ensign Peak Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.7K Sell
9,200
-250
-3% -$2.24K ﹤0.01% 1648
2026
Q1 		$76.9K Hold
9,450
– – ﹤0.01% 1620
2025
Q4 		$63.5K Sell
9,450
-19,550
-67% -$147K ﹤0.01% 1650
2025
Q3 		$251K Sell
29,000
-17,450
-38% -$136K ﹤0.01% 1614
2025
Q2 		$293K Sell
46,450
-5,950
-11% -$39.4K ﹤0.01% 1656
2025
Q1 		$336K Hold
52,400
– – ﹤0.01% 1629
2024
Q4 		$421K Buy
52,400
+7,500
+17% +$72.3K ﹤0.01% 1642
2024
Q3 		$567K Hold
44,900
– – ﹤0.01% 1572
2024
Q2 		$568K Buy
44,900
+1,300
+3% +$13.1K ﹤0.01% 1567
2024
Q1 		$208K Sell
43,600
-2,200
-5% -$10.2K ﹤0.01% 1704
2023
Q4 		$220K Buy
45,800
+1,150
+3% +$7.04K ﹤0.01% 1717
2023
Q3 		$323K Buy
+44,650
New +$357K ﹤0.01% 1678
2022
Q4 		– Sell
-69,335
Closed -$1.26M – 2078
2022
Q3 		$1.26M Buy
69,335
+17,775
+34% +$770K ﹤0.01% 956
2022
Q2 		$2.65M Buy
51,560
+6,740
+15% +$349K 0.01% 704
2022
Q1 		$3.3M Buy
44,820
+15,420
+52% +$1.38M 0.01% 707
2021
Q4 		$4.21M Buy
29,400
+12,765
+77% +$2.19M 0.01% 714
2021
Q3 		$3.45M Buy
16,635
+6,231
+60% +$1.37M 0.01% 813
2021
Q2 		$2.21M Buy
10,404
+1,400
+16% +$257K ﹤0.01% 1072
2021
Q1 		$1.63M Sell
9,004
-6,061
-40% -$1.21M ﹤0.01% 1208
2020
Q4 		$1.68M Sell
15,065
-28,066
-65% -$2.98M ﹤0.01% 1162
2020
Q3 		$4.67M Buy
+43,131
New +$5.25M 0.01% 650

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Ensign Peak Advisors's NVAX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Novavax (NVAX) stake by 2.6% in Q2 2026, selling an estimated $2.24K and leaving 9,200 shares worth $86.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Ensign Peak Advisors first reported a position in NVAX in Q3 2020 and has held it in 21 quarters since. The position peaked at $4.67M in Q3 2020. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Ensign Peak Advisors held 9,200 shares of Novavax worth $86.7K as of Q2 2026.
  • Ensign Peak Advisors sold 250 Novavax shares in Q2 2026, an estimated $2.24K.
  • Novavax made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1648 holding.
  • Ensign Peak Advisors first reported a position in Novavax in Q3 2020 and has held it in 21 quarters since.
  • Ensign Peak Advisors's Novavax position peaked at $4.67M in Q3 2020.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.